Quick Overview
- Johnson & Johnson delivered Q1 adjusted earnings of $2.70 per share, surpassing Wall Street’s $2.68 projection, while revenues reached $24.1 billion versus the anticipated $23.6 billion.
- The pharmaceutical segment grew 11.2% compared to last year, hitting $15.4 billion, with Darzalex generating $4.0B and Tremfya contributing $1.6B.
- Management elevated its 2026 full-year revenue forecast to $100.8 billion and adjusted earnings per share outlook to $11.55.
- According to Truist Securities, J&J’s recently approved psoriasis medication Icotyde has potential to achieve approximately $10 billion in peak annual revenue.
- Shares of JNJ have climbed 15% since the start of 2026, significantly outpacing the S&P 500’s 0.6-1% advance.
Johnson & Johnson unveiled its first-quarter 2026 financial performance before market open on Tuesday, delivering both revenue and profit figures that exceeded analyst projections.
Revenue for the quarter totaled $24.1 billion, representing a 10% increase from the corresponding quarter last year and outpacing the Wall Street consensus of $23.6 billion gathered by FactSet. The company’s adjusted profit per share reached $2.70, marginally beating the $2.68 expectation.
Shares climbed approximately 1.2% during pre-market hours after the announcement.
This quarter marks another milestone in J&J’s ongoing transformation. The healthcare conglomerate has been shifting its strategic focus away from consumer products in recent years — divesting the Kenvue business, which is currently being purchased by Kimberly-Clark — to emphasize its pharmaceutical and medical technology operations.
The pharmaceutical division stood out as the primary growth driver, expanding 11.2% year-on-year to reach $15.4 billion. This performance exceeded the FactSet consensus projection of $15.2 billion.
Darzalex, the company’s leading treatment for multiple myeloma, generated $4.0 billion during the quarter, climbing from $3.2 billion in the prior-year period. Analysts had forecast $3.9 billion.
Tremfya, an IL-23 inhibitor prescribed for autoimmune diseases, recorded $1.6 billion in quarterly revenue, jumping significantly from $956 million twelve months earlier and comfortably surpassing the $1.4 billion analyst estimate.
Strategic Immunology Advances
Regulatory authorities approved Tremfya’s subcutaneous formulation last September for individuals with ulcerative colitis and Crohn’s disease, establishing it as the first medication in its category that patients can administer independently at home. This development provides a competitive edge against AbbVie’s Skyrizi, which necessitates clinic-based infusions during initial treatment.
Last month, J&J secured FDA clearance for Icotyde, an innovative oral IL-23 inhibitor tablet for plaque psoriasis treatment, originating from a 2017 licensing agreement with Protagonist Therapeutics. Truist Securities analyst Srikripa Devarakonda projects Icotyde could eventually generate approximately $10 billion in annual peak revenue. The company has yet to report any commercial sales data.
The medical technology segment contributed $8.6 billion in revenue, matching analyst predictions.
Net profit totaled $5.2 billion, falling short of the FactSet projection of $6.5 billion — marking the second straight quarter where bottom-line earnings missed Wall Street’s expectations.
Updated Outlook and Litigation Challenges
For 2026, J&J has revised its full-year revenue projection upward to $100.8 billion from the previous $100.5 billion estimate. The company also increased its adjusted earnings per share guidance to $11.55 from $11.03. Wall Street had anticipated $11.54 per share and $100.6 billion in total sales.
The healthcare giant continues managing significant litigation exposure. As of Q4 2025’s conclusion, J&J confronted 74,360 legal claims alleging it deliberately marketed talcum powder products contaminated with carcinogenic asbestos. The company’s latest effort to settle these matters through a bankruptcy petition filed by its Red River Talc subsidiary was rejected by a Texas court, permitting individual cases to move forward.
J&J continues asserting its baby powder product, currently marketed under the Kenvue brand, remains safe and free from asbestos contamination.
Among 29 analyst firms monitored by FactSet, 17 assign JNJ a Buy rating or its equivalent. Two analysts rate it a Sell.
JNJ stock has advanced 15% year-to-date in 2026, substantially outperforming the S&P 500’s approximately 0.6% to 1% gain during the identical timeframe.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
